Evidence map›Paper›PMID 32265684›Full record

ReviewFrontiers in aging neuroscience2020

Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson's Disease.

Arianna Bellucci, Luigi Bubacco, Francesca Longhena, Edoardo Parrella, Gaia Faustini, Vanessa Porrini, Federica Bono, Cristina Missale, Marina Pizzi

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Isotopically enrichedScientific reports · 2026
    Article
  3. Article
  4. LRRK2NPJ Parkinson's disease · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Involvement of KAntioxidants (Basel, Switzerland) · 2024
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Arianna BellucciDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Luigi BubaccoDepartment of Biology, University of Padua, Padua, Italy.
Francesca LonghenaDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Edoardo ParrellaDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Gaia FaustiniDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Vanessa PorriniDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Federica BonoDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Cristina MissaleDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Marina PizziDivision of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
University of Brescia · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The loss of dopaminergic neurons of the nigrostriatal system underlies the onset of the typical motor symptoms of Parkinson's disease (PD). Lewy bodies (LB) and Lewy neurites (LN), proteinaceous inclusions mainly composed of insoluble α-synuclein (α-syn) fibrils are key neuropathological hallmarks of the brain of affected patients. Compelling evidence supports that in the early prodromal phases of PD, synaptic terminal and axonal alterations initiate and drive a retrograde degeneration process culminating with the loss of nigral dopaminergic neurons. This notwithstanding, the molecular triggers remain to be fully elucidated. Although it has been shown that α-syn fibrillary aggregation can induce early synaptic and axonal impairment and cause nigrostriatal degeneration, we still ignore how and why α-syn fibrillation begins. Nuclear factor-κB (NF-κB) transcription factors, key regulators of inflammation and apoptosis, are involved in the brain programming of systemic aging as well as in the pathogenesis of several neurodegenerative diseases. The NF-κB family of factors consists of five different subunits (c-Rel, p65/RelA, p50, RelB, and p52), which combine to form transcriptionally active dimers. Different findings point out a role of RelA in PD. Interestingly, the nuclear content of RelA is abnormally increased in nigral dopamine (DA) neurons and glial cells of PD patients. Inhibition of RelA exert neuroprotection against (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) MPTP and 1-methyl-4-phenylpyridinium (MPP+) toxicity, suggesting that this factor decreases neuronal resilience. Conversely, the c-Rel subunit can exert neuroprotective actions. We recently described that mice deficient for c-Rel develop a PD-like motor and non-motor phenotype characterized by progressive brain α-syn accumulation and early synaptic changes preceding the frank loss of nigrostriatal neurons. This evidence supports that dysregulations in this transcription factors may be involved in the onset of PD. This review highlights observations supporting a possible interplay between NF-κB dysregulation and α-syn pathology in PD, with the aim to disclose novel potential mechanisms involved in the pathogenesis of this disorder.

Indexed as

c-Rel ko micenuclear factor-κB (NF-κB)Parkinson’s diseaseRel Aα-synuclein

Identifiers

PMID32265684
PMCPMC7105602
OpenAlexW3013963964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.